



CADTH

pCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

## New Resource: Introducing Cancer Drug Pipeline Information for Patient Advocacy Groups

September 28, 2015

Hello,

We are very pleased to provide a new centralized source of information for patient advocacy groups that details the anticipated cancer drug products or indications that could enter the Canadian market. The [Cancer Drug Pipeline Information for Patient Advocacy Groups](#) is a collaboration between the Canadian Cancer Action Network (CCAN) and the CADTH pan-Canadian Oncology Drug Review (pCODR) program. It aims to support patient groups by providing longer lead times to make a submission to the pCODR program.

*"I'm very proud and excited to have been part of the collaborative process to create valuable resources to support patient advocacy groups. The Cancer Drug Pipeline Information for Patient Advocacy Groups will let patients have a peek into the future and learn what new cancer drugs could be coming over the next few years."*

*Dr. James (Jim) Gowing, Project Lead,  
Health Technology Assessment File,  
Canadian Cancer Action Network*

The [Cancer Drug Pipeline Information for Patient Advocacy Groups](#) is intended to identify potential new cancer drug products or indications that could be submitted to pCODR in the near future. The published information is obtained from publicly available sources, including the US Food and Drug Administration.\*

We believe that the [Cancer Drug Pipeline Information for Patient Advocacy Groups](#) will help your organization be more prepared to participate in the review process by giving you longer lead times to prepare your submission. To ensure as many patient advocacy groups as possible know that this resource is available on the [CCAN](#) and [CADTH](#) websites, we ask that you share this information with your contacts by forwarding this notice.

If you have any questions, please contact CCAN at [info@canceraction.ca](mailto:info@canceraction.ca) or CADTH at [requests@cadth.ca](mailto:requests@cadth.ca).

*\* Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline.*